FOLFIRI + E7820

Phase 1/2Terminated
0 watching 0 views this week Active
41
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Colon Cancer

Conditions

Colon Cancer, Rectal Cancer

Trial Timeline

Sep 30, 2011 → Jun 22, 2015

About FOLFIRI + E7820

FOLFIRI + E7820 is a phase 1/2 stage product being developed by Eisai for Colon Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01347645. Target conditions include Colon Cancer, Rectal Cancer.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT01347645Phase 1/2Terminated